Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean W Fanning

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Nature Communications|September 3, 2024
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cellsRachid Safi, Suzanne E Wardell, Paige Watkinson, et al.
Journal of Medicinal Chemistry|February 13, 2025
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)Paige J Monsen, Prashant V Bommi, Arabela A Grigorescu, et al.
ACS Omega|June 16, 2025
Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD)Raymond A Ng, Susanna Barratt, Alison Parisian, et al.
Cancer Letters|June 22, 2024
NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumorsHashni Epa Vidana Gamage, Sayyed Hamed Shahoei, Yu Wang, et al.
Cancer Letters|June 29, 2024
Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cellsHashni Epa Vidana Gamage, Samuel T Albright, Amanda J Smith, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2023
Re-education of myeloid immune cells to reduce regulatory T cell expansion and impede breast cancer progressionHashni Epa Vidana Gamage, Sayyed Hamed Shahoei, Samuel T Albright, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancerJohn T Phoenix, Audris Budreika, Devin A Schmeck, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Nature Communications|September 3, 2024
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cellsRachid Safi, Suzanne E Wardell, Paige Watkinson, et al.
Journal of Medicinal Chemistry|February 13, 2025
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)Paige J Monsen, Prashant V Bommi, Arabela A Grigorescu, et al.
ACS Omega|June 16, 2025
Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD)Raymond A Ng, Susanna Barratt, Alison Parisian, et al.
Cancer Letters|June 22, 2024
NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumorsHashni Epa Vidana Gamage, Sayyed Hamed Shahoei, Yu Wang, et al.
Cancer Letters|June 29, 2024
Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cellsHashni Epa Vidana Gamage, Samuel T Albright, Amanda J Smith, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2023
Re-education of myeloid immune cells to reduce regulatory T cell expansion and impede breast cancer progressionHashni Epa Vidana Gamage, Sayyed Hamed Shahoei, Samuel T Albright, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancerJohn T Phoenix, Audris Budreika, Devin A Schmeck, et al.
Pageof 4